Larimar Therapeutics Net Income vs. Cash Flow From Operations
| LRMR Stock | USD 5.50 0.27 5.16% |
Net Loss | First Reported 2014-06-30 | Previous Quarter -26.2 M | Current Value -47.7 M | Quarterly Volatility 7.9 M |
For Larimar Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Larimar Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Larimar Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Larimar Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Larimar Therapeutics over time as well as its relative position and ranking within its peers.
Check out Correlation Analysis. Can Biotechnology industry sustain growth momentum? Does Larimar have expansion opportunities? Factors like these will boost the valuation of Larimar Therapeutics. Expected growth trajectory for Larimar significantly influences the price investors are willing to assign. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Larimar Therapeutics demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Larimar Therapeutics's market price often diverges from its book value, the accounting figure shown on Larimar's balance sheet. Smart investors calculate Larimar Therapeutics' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Since Larimar Therapeutics' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Understanding that Larimar Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Larimar Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. However, Larimar Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Larimar Therapeutics Cash Flow From Operations vs. Net Income Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Larimar Therapeutics's current stock value. Our valuation model uses many indicators to compare Larimar Therapeutics value to that of its competitors to determine the firm's financial worth. Larimar Therapeutics is rated third overall in net income category among its peers. It is rated fifth overall in cash flow from operations category among its peers . Larimar Therapeutics reported last year Net Loss of (72.54 Million). Comparative valuation analysis is a catch-all technique that is used if you cannot value Larimar Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Larimar Cash Flow From Operations vs. Net Income
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Larimar Therapeutics |
| = | (80.6 M) |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Larimar Therapeutics |
| = | (70.76 M) |
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
Larimar Cash Flow From Operations Comparison
Larimar Therapeutics is currently under evaluation in cash flow from operations category among its peers.
Larimar Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Larimar Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Larimar Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Larimar Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Larimar Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 170.2 K | 178.7 K | |
| Operating Income | -81.8 M | -77.7 M | |
| Income Before Tax | -72.5 M | -68.9 M | |
| Total Other Income Expense Net | 11.8 M | 12.4 M | |
| Net Loss | -72.5 M | -68.9 M | |
| Interest Income | 223.2 K | 365.6 K | |
| Net Loss | -40.7 M | -42.7 M | |
| Income Tax Expense | -1.3 M | -1.4 M | |
| Net Loss | -72.5 M | -68.9 M | |
| Non Operating Income Net Other | 1.3 M | 821.1 K | |
| Change To Netincome | 7.6 M | 8 M | |
| Net Loss | (1.18) | (1.24) | |
| Income Quality | 1.01 | 0.98 | |
| Net Income Per E B T | 1.15 | 1.09 |
Larimar Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Larimar Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Larimar Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Larimar Therapeutics' important profitability drivers and their relationship over time.
Larimar Therapeutics Earnings Estimation Breakdown
The calculation of Larimar Therapeutics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Larimar Therapeutics is estimated to be -0.459625 with the future projection ranging from a low of -0.635 to a high of -0.3475. Please be aware that this consensus of annual earnings estimates for Larimar Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.64 Lowest | Expected EPS | -0.35 Highest |
Larimar Therapeutics Earnings Projection Consensus
Suppose the current estimates of Larimar Therapeutics' value are higher than the current market price of the Larimar Therapeutics stock. In this case, investors may conclude that Larimar Therapeutics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Larimar Therapeutics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2026 | Current EPS (TTM) | |
| 11 | 62.63% | 0.0 | -0.459625 | -1.96 |
Larimar Therapeutics Earnings per Share Projection vs Actual
Actual Earning per Share of Larimar Therapeutics refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Larimar Therapeutics predict the company's earnings will be in the future. The higher the earnings per share of Larimar Therapeutics, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Larimar Therapeutics Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Larimar Therapeutics, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Larimar Therapeutics should always be considered in relation to other companies to make a more educated investment decision.Larimar Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Larimar Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
null | null | null | null | null | 0 | ||
null | null | null | null | null | 0 | ||
2025-11-05 | 2025-09-30 | -0.4128 | -0.61 | -0.1972 | 47 | ||
2025-08-05 | 2025-06-30 | -0.4803 | -0.41 | 0.0703 | 14 | ||
2025-05-07 | 2025-03-31 | -0.4091 | -0.46 | -0.0509 | 12 | ||
2025-03-12 | 2024-12-31 | -0.3194 | -0.45 | -0.1306 | 40 | ||
2024-10-30 | 2024-09-30 | -0.37 | -0.24 | 0.13 | 35 | ||
2024-08-07 | 2024-06-30 | -0.31 | -0.34 | -0.03 | 9 | ||
2024-05-09 | 2024-03-31 | -0.23 | -0.27 | -0.04 | 17 | ||
2024-03-14 | 2023-12-31 | -0.25 | -0.3 | -0.05 | 20 | ||
2023-11-14 | 2023-09-30 | -0.22 | -0.21 | 0.01 | 4 | ||
2023-08-10 | 2023-06-30 | -0.19 | -0.19 | 0.0 | 0 | ||
2023-05-15 | 2023-03-31 | -0.25 | -0.15 | 0.1 | 40 | ||
2023-03-14 | 2022-12-31 | -0.37 | -0.21 | 0.16 | 43 | ||
2022-11-10 | 2022-09-30 | -0.42 | -0.37 | 0.05 | 11 | ||
2022-08-11 | 2022-06-30 | -0.57 | -0.47 | 0.1 | 17 | ||
2022-05-12 | 2022-03-31 | -0.51 | -0.49 | 0.02 | 3 | ||
2022-03-25 | 2021-12-31 | -0.72 | -0.5 | 0.22 | 30 | ||
2021-11-12 | 2021-09-30 | -0.64 | -0.92 | -0.28 | 43 | ||
2021-08-12 | 2021-06-30 | -0.75 | -0.79 | -0.04 | 5 | ||
2021-05-10 | 2021-03-31 | -0.86 | -0.76 | 0.1 | 11 | ||
2021-03-04 | 2020-12-31 | -0.7 | -0.89 | -0.19 | 27 | ||
2020-11-10 | 2020-09-30 | -2.28 | -0.64 | 1.64 | 71 | ||
2020-08-11 | 2020-06-30 | -2.16 | -1.21 | 0.95 | 43 | ||
2020-05-08 | 2020-03-31 | -2.28 | -1.2 | 1.08 | 47 | ||
2020-03-05 | 2019-12-31 | -2.28 | -2.28 | 0.0 | 0 | ||
2019-11-06 | 2019-09-30 | -3.2 | -2.88 | 0.32 | 10 | ||
2019-08-08 | 2019-06-30 | -4.38 | -3.84 | 0.54 | 12 | ||
2019-05-09 | 2019-03-31 | -5.09 | -4.2 | 0.89 | 17 | ||
2019-03-11 | 2018-12-31 | -5.26 | -4.68 | 0.58 | 11 | ||
2018-11-07 | 2018-09-30 | -5.64 | -4.92 | 0.72 | 12 | ||
2018-08-07 | 2018-06-30 | -7.08 | -6.84 | 0.24 | 3 | ||
2018-05-08 | 2018-03-31 | -6.18 | -6.96 | -0.78 | 12 | ||
2018-03-06 | 2017-12-31 | -6.84 | -5.76 | 1.08 | 15 | ||
2017-11-07 | 2017-09-30 | -6.92 | -5.52 | 1.4 | 20 | ||
2017-08-08 | 2017-06-30 | -6.24 | -5.88 | 0.36 | 5 | ||
2017-05-09 | 2017-03-31 | -5.21 | -5.76 | -0.55 | 10 | ||
2017-03-09 | 2016-12-31 | -6.03 | -4.56 | 1.47 | 24 | ||
2016-11-09 | 2016-09-30 | -7.28 | -6.48 | 0.8 | 10 | ||
2016-08-04 | 2016-06-30 | -7.94 | -6.6 | 1.34 | 16 | ||
2016-05-10 | 2016-03-31 | -8.85 | -7.8 | 1.05 | 11 | ||
2016-03-09 | 2015-12-31 | -9.58 | -10.2 | -0.62 | 6 | ||
2015-11-10 | 2015-09-30 | -9.5 | -8.76 | 0.74 | 7 | ||
2015-08-11 | 2015-06-30 | -8.49 | -7.92 | 0.57 | 6 | ||
2015-05-12 | 2015-03-31 | -7.74 | -6.36 | 1.38 | 17 | ||
2015-03-19 | 2014-12-31 | -7.85 | -5.76 | 2.09 | 26 | ||
2014-11-11 | 2014-09-30 | -11.07 | -7.2 | 3.87 | 34 | ||
2014-08-13 | 2014-06-30 | -30.93 | -33.12 | -2.19 | 7 |
Use Larimar Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Larimar Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Larimar Therapeutics will appreciate offsetting losses from the drop in the long position's value.Larimar Therapeutics Pair Trading
Larimar Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to Larimar Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Larimar Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Larimar Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Larimar Therapeutics to buy it.
The correlation of Larimar Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Larimar Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Larimar Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Larimar Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Larimar Therapeutics position
In addition to having Larimar Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Top Crypto Assets Thematic Idea Now
Top Crypto Assets
An experimental p2p digital currency that is accepted by many vendors in null. The Top Crypto Assets theme has 0 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Top Crypto Assets Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Larimar Stock Analysis
When running Larimar Therapeutics' price analysis, check to measure Larimar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Larimar Therapeutics is operating at the current time. Most of Larimar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Larimar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Larimar Therapeutics' price. Additionally, you may evaluate how the addition of Larimar Therapeutics to your portfolios can decrease your overall portfolio volatility.